Hamburg, Germany-based apoQlar designed VSI HoloMedicine to enable surgeons to plan complex procedures with 3D holographic technology.
According to a news release, FDA clearance makes the U.S. the 30th country to clear the apoQlar technology. The company intends to distribute in the U.S. through its Miami, Florida-based subsidiary. It expects commercial availability in the second quarter of 2023.
Following the clearance, apoQlar said it intends to raise a Series A funding round. It marks the medical metaverse company’s first-ever fundraising campaign as it looks to scale VSI HoloMedicine.
“With mixed reality, we are no longer bound to physical objects in a physical world,” said apoQlar co-founder and CEO Sirko Pelzl. “We can leverage digital objects and services on top of the real world for equal or greater utility and usually at a fraction of the cost. Mixed reality is a completely new way for people, and in our case surgeons, physicians and technologists, to continue to experience the real world around them but with an entire virtual layer placed on top.”
More about apoQlar’s VSI HoloMedicine platform
apoQlar said its system gives surgeons something akin to an “x-ray vision” perspective in surgical planning.
It uses 3D holographic technology for surgeons to visualize medical data inside or outside of the operating room. It uses Microsoft’s HoloLens 2 mixed reality head-mounted display.
Surgeons can transform otherwise flat CT, angio CT, MRI, CBCT, PET, and SPECT sources into interactive 3D holograms. According to Sirko, it enhances the overall planning process for surgeons.
“FDA clearance marks a major milestone for us. We are a young company, but this serves as a true testament of our collective team mindset and diligence” said Liliana Duarte, COO of apoQlar. This is the latest achievement for apoQlar in their global expansion plan and serves as a tailwind for further market expansion efforts into South-East Asia, India, and the Gulf Coast States for 2023.